Abstract: SA-PO749
Clinical Presentation and Outcomes of SARS-CoV-2 Infection in Patients with Pauci-Immune Glomerulonephritis
Session Information
- ANCA-Associated Vasculitis, Anti-GBM Disease, and Other RPGN
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
- Dounousi, Evangelia, Panepistemio Ioanninon, Ioannina, Epirus, Greece
- Gkalitsiou, Dimitra, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece
- Kantartzi, Konstantia, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece
- Liakopoulos, Vassilios, Aristoteleio Panepistemio Thessalonikes, Thessalonike, Kentrikḗ Makedonía, Greece
- Marinaki, Smaragdi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Greece
- Moustakas, Georgios, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece
- Karagiannis, Minas, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
- Nikolopoulos, Petros, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
- Panagoutsos, Stylianos A., Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece
- Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
Background
SARS-CoV-2 infection is characterized by multi-system involvement, affecting not only the respiratory system1,2. This study aimed to outline the clinical presentation and outcomes of SARS-CoV-2 infection in patients with pauci-immune GN (PIGN).
Methods
A retrospective analysis was conducted on 29 individuals with PIGN and positive SARS-CoV-2 PCR test, excluding those in end-stage kidney disease (ESKD) prior to infection. Data encompassed immunosuppressive regimens at PIGN diagnosis, treatment outcomes, SARS-CoV-2 infection’s clinical course and outcome of PIGN post infection.
Results
The mean age of patients was 61.0(±16.4) years, with 16(55.1%) being female. Upon SARS-CoV-2 infection, 12(41.3%) were on immunosuppressive therapy, of whom 4 (13.7%) were on rituximab maintenance therapy. Almost all patients were symptomatic in terms of the infection and 7(24.1%) required hospitalization. 23(88.4%) experienced complete recovery from Covid-19, 3(3.1%) had prolonged symptoms and 3(11.5%) died due to Covid-19. Among patients in remission, 1(3.8%) experienced a relapse of PIGN following SARS-CoV-2 infection.
Conclusion
In this cohort of patients with PIGN, SARS-CoV-2 infection impacted morbidity and mortality of this vulnerable population.
Demographics, baseline patients’ characteristics, symptoms and outcomes of SARS-CoV-2 infection and GN.
| Parameter Ν(%) or mean (SD) | N=29 |
| Age at diagnosis of GN (years) | 61,0 (16,4) |
| Gender (males) | 13/29 |
| Time since diagnostic biopsy (months) | 61,2(56,2) |
| Induction treatment Corticosteroids Cyclophosphamide Mycophenolate mofetil Rituximab | 29(100) 20 (95,2) 1(3,4) 7 (26,9) |
| First outcome of GN Remission Relapse | 27 (96,4) 1 (3,5) |
| Immunosuppressive treatment at SARS-CoV-2 infection Mycophenolate mofetil Glucocorticoids Rituximab AZA | N=12 2 3 4 3 |
| Symptoms Arthralgias Μyalgias Fever Fatigue Cough Shortness of breath | 2(6,9) 1(3,4) 22 (75,8) 3 (10,3) 9 (31,0) 1 (3,4) |
| Hospitalization requirement | 7 (24,1) |
| Mechanical ventilation requirement | 1(14,3) |
| SARS-CoV-2 outcome Complete recovery Death Long COVID | 26 23 (88,4) 3 (11,5) 0 |
| Relapse of GN after SARS-CoV-2 infection | 1 (3,8) |